Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
for source : Investors.biomarin.com save search
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
Published: 2023-11-28 (Crawled : 14:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -0.21%
H: 0.12%
C: -0.74%
roctavian health germany insurance agreement
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
Published: 2023-09-21 (Crawled : 14:30) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -0.68%
H: 0.52%
C: -1.72%
voxzogo children achondroplasia meeting growth
U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A
Published: 2023-06-29 (Crawled : 19:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 1.2%
H: 1.97%
C: -3.69%
drug food therapy
FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5
Published: 2023-03-07 (Crawled : 22:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 0.12%
H: 1.14%
C: 0.83%
voxzogo fda drug children application achondroplasia injection
BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
Published: 2023-02-27 (Crawled : 22:00) - investors.biomarin.com
SNY | News | $45.55 -1.21% 250K
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -3.82%
H: 3.69%
C: 0.29%
voxzogo global year growth
European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
Published: 2023-01-03 (Crawled : 22:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 3.06%
H: 3.12%
C: 3.12%
voxzogo children extension application injection achondroplasia
BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
Published: 2022-11-23 (Crawled : 14:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 4.29%
H: 4.89%
C: 2.84%
fda review
FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A
Published: 2022-10-12 (Crawled : 21:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -1.7%
H: 3.35%
C: 2.24%
fda application license therapy
BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA
Published: 2022-09-29 (Crawled : 20:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -0.08%
H: 2.07%
C: -0.26%
fda application license therapy
BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report
Published: 2022-09-15 (Crawled : 13:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -0.26%
H: 1.82%
C: 1.69%
report therapy
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed
Published: 2022-06-21 (Crawled : 20:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 0.66%
H: 6.95%
C: 4.08%
voxzogo treatment japan children granted approval injection growth achondroplasia
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
Published: 2022-05-31 (Crawled : 13:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 1.91%
H: 0.01%
C: -6.6%
ongoing therapy phase 1
BioMarin Sells Priority Review Voucher for $110 Million
Published: 2022-02-09 (Crawled : 13:30) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4
Published: 2022-02-02 (Crawled : 22:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -3.07%
H: 1.15%
C: 0.75%
europe order haemophilia
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
Published: 2021-12-16 (Crawled : 22:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -0.31%
H: 5.57%
C: 3.78%
cardio therapeutics disease gene therapies cardiovascular collaboration gene therapy therapy
BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
Published: 2021-11-19 (Crawled : 15:30) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 0.75%
H: 9.79%
C: 9.49%
fda drop fda approval injection children growth approval 25000 people voxzogo achondroplasia
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Published: 2021-07-15 (Crawled : 13:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: -0.36%
H: 0.76%
C: 0.23%
europe authorized application
BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Published: 2021-06-28 (Crawled : 13:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 1.18%
H: 0.63%
C: -1.59%
europe authorized application
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Published: 2021-06-25 (Crawled : 12:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 0.66%
H: 1.39%
C: 0.55%
treatment europe drop positive children growth chmp achondroplasia
European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A
Published: 2021-05-24 (Crawled : 13:00) - investors.biomarin.com
BMRN | News S | $90.46 -0.01% 84K
|
Health Technology
|
| O: 0.67%
H: 0.36%
C: -1.36%
treatment europe granted grant
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
TIRX | $1.13 133.09% 44M
|
AGBA | $0.8978 124.45% 60M
|
Finance
BPTH | $6.18 90.74% 39M
|
Health Technology
INVO | $1.44 89.47% 3M
|
Health Technology
SINT | $0.0588 57.64% 240M
|
Health Technology
XPON | $2.66 37.82% 5.2M
|
THCH | $1.38 32.69% 9.9M
|
n/a
ALRN | $5.605 31.88% 210K
|
Health Technology
HOLO | $2.92 30.36% 22M
|
VTNR S | $1.25 27.66% 3.2M
|
Industrial Services
Your saved searches
Save your searches and get alerts when important news are released.